Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Inosine modulates antitumor immunity: Checkpoint blockade immunotherapy harnesses the immune system to kill cancer cells and has been used with great success to treat certain tumors, but not all cancer patients respond. The efficacy of checkpoint blockade immunotherapy has been shown to depend on the presence of distinct, beneficial bacteria residing in the gut of patients, but how the microbiome mediates such beneficial effects is unclear. Mager et al. found that specific bacteria produce a metabolite called inosine that enhances the effect of checkpoint blockade immunotherapy (see the Perspective by Shaikh and Sears). In mouse models, inosine, together with proinflammatory stimuli and immunotherapy, strongly enhanced the antitumor capacities of T cells in multiple tumor types, including colorectal cancer, bladder cancer, and melanoma. Science , this issue p. 1481 ; see also p. 1427
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Inosine, the purine metabolite of Akkermansia muciniphila and Bifidobacterium pseudolongum (B. pseudolongum), plays a vital role in improving the efficacy of ICI [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The inosine-A2AR-cAMP-PKA signaling cascade led to the phosphorylation of cAMP response element-binding protein (pCREB), which upregulated IL12Rβ2 and IFNγ transcription and promoted Th1-cell differentiation and accumulation in the TME [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“The gut microbial metabolite inosine could improve the efficacy of ICI by acting on adenosine 2A receptor (A2AR) on T lymphocytes in intestinal cancer, bladder cancer, and melanoma mouse models [51].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“Moreover, specific gut microbes, such as Bifidobacterium [16, 33, 51, 141], Akkermansia [31, 38], Enterococcus [15, 33, 141], Faecalibacterium [49, 142], and Ruminococcaceae [32], play the role of immune adjuvants in ICI immunotherapy.”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [51]
In the citing paper
“for example, anti-CTLA-4 appears to modify gut barrier integrity 51 and thus could feasibly change microbial compositions”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [51]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
16S ribosomal DNA amplification for phylogenetic study
Weisburg, W. G., Barns, S. M., Pelletier, D. A., & Lane, D. J. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.2.697-703.1991 · Cited by 11,934
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cited by
Items 301–400 of 1,004
Metabolic rewiring and communication in cancer immunity
Chapman, N. M., & Chi, H. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.02.001 · Cited by 49
“140 139 Beyond intestinal microbes, the intratumoral microbiome is also an emerging regulator of tumor development and progression, 141 suggesting that local production of metabolites by intratumoral microbiota may also contribute to cancer immunity.”
BackgroundMicrobiota-mediated mechanisms of mucosal immunity across the lifespan
Iliev, I. D., Blander, J. M., Collins, N., Guo, C., Longman, R., Sonnenberg, G. F., Zeng, M. Y., & Artis, D. (2025) · Nature Immunology · doi:10.1038/s41590-025-02281-w · Cited by 66
Targeting the gut microbiome: An emerging trend in hematopoietic stem cell transplantation
Čierniková, S., Kasperová, B. J., Drgoňa, Ľ., Smolková, B., Števurková, V., & Mego, M. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100790 · Cited by 44
A Highly Conductive All‐Carbon Linked 3D Covalent Organic Framework Film
Yang, Y., Mallick, S., Izquierdo‐Ruiz, F., Schäfer, C., Xing, X., Rahm, M., & Börjesson, K. (2021) · Small · doi:10.1002/smll.202103152 · Cited by 44
Bacteria in cancer therapy: A new generation of weapons
Fan, J., Huang, Y., Li, Y., Muluh, T. A., Fu, S., & Wu, J. (2022) · Cancer Medicine · doi:10.1002/cam4.4799 · Cited by 46
Tomita, Y., Sakata, S., Imamura, K., Iyama, S., Jodai, T., Saruwatari, K., Hamada, S., Akaike, K., Anai, M., Fukusima, K., et al. (2023) · Cancers · doi:10.3390/cancers16010047 · Cited by 48
Orberg, E. T., Meedt, E., Hiergeist, A., Xue, J., Heinrich, P., Ru, J., Ghimire, S., Miltiadous, O., Lindner, S., Tiefgraber, M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00669-x · Cited by 49
“Purine metabolism was recently linked to efficacy of immunotherapy 31 , while vitamin B synthesis 32 was associated with protection from colitis.”
Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine
Meza‐Perez, S., Liu, M., Silva-Sánchez, A., Morrow, C. D., Eipers, P. G., Lefkowitz, E. J., Ptacek, T., Scharer, C. D., Rosenberg, A. F., Hill, D. D., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.06.003 · Cited by 44
Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors
Wang, L., Londono, L. M., Cowell, J., Saatci, Ö., Aras, M., Ersan, P. G., Serra, S., Pei, H., Clift, R., Zhao, Q., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0340 · Cited by 46
“Also, inosine generated by microbiome can weakly stimulate adenosine A2A receptors (17), which can provide basal level A2AR signaling required for T-cell maintenance and growth factor responsiveness of CD8þT cells (6, 16, 17).”
BackgroundCheng, S., Han, Z., Dai, D., Li, F., Zhang, X., Lu, M. S., Lü, Z., Wang, X., Zhou, J., Li, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101355 · Cited by 58
Engineered Microorganisms for Advancing Tumor Therapy
Jia, J., Wang, X., Lin, X., & Zhao, Y. (2024) · Advanced Materials · doi:10.1002/adma.202313389 · Cited by 46
Su, X., Li, J., Xu, X., Ye, Y., Wang, C., Pang, G., Liu, W., Liu, A., Zhao, C., & Hao, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05552-6 · Cited by 48
“Another series of studies discovered that Bifidum pseudolonidum produces the metabolite adenosine through T cell-specific inosine A 2A receptor signaling, which inhibits tumor growth and enhances anti-tumor immunity when administered together with anti-CTLA-4 antibody, inosine, and CpG [244].”
BackgroundWekking, D., van den Ende, T., Bijlsma, M. F., Vidal-Itriago, A., Nieuwdorp, M., & van Laarhoven, H. W. M. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103025 · Cited by 46
Bachem, A., Clarke, M. V., Kong, G., Tarasova, I., Dryburgh, L., Kosack, L., Lee, A. R., Newland, L. G. M., Wagner, T., Bawden, E., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.004 · Cited by 51
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40
“pseudolongum—produce inosine and enhance the effects of anti–CTLA-4 therapy (76).”
BackgroundCross-reactivity between microbial and tumor antigens
Zitvogel, L., & Kroemer, G. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102171 · Cited by 40
Machine Learning Predicts Drug Metabolism and Bioaccumulation by Intestinal Microbiota
McCoubrey, L. E., Thomaidou, S., Elbadawi, M., Gaisford, S., Orlu, M., & Basit, A. W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122001 · Cited by 47
“The inter-individual pharmacokinetic variability arising from the microbial depletion of drugs could contribute towards treatment failure or toxicity in some patients, in addition to difficulties finding an optimum dose [28–30].”
BackgroundNoecker, C. A., Sánchez, J. M., Bisanz, J. E., Escalante, V., Alexander, M., Trepka, K. R., Heinken, A., Liu, Y., Dodd, D., Thiele, I., et al. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002125 · Cited by 50
“Interestingly, several small molecules produced by E . lenta in EDM1 and in mice are known to impact host immune signaling, including indole-3-acetate [62] and inosine [63,64].”
Unveiling the intratumoral microbiota within cancer landscapes
Che, S., Yan, Z., Feng, Y., & Hai, Z. (2024) · iScience · doi:10.1016/j.isci.2024.109893 · Cited by 44
Zhou, Y., Han, W., Feng, Y., Wang, Y., Sun, T., & Xu, J. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5661 · Cited by 43
“HDAC inhibitors enhance the antitumor therapeutic efficacy of ICIs by modifying the immunosuppressive function of TAMs and impeding the ingress of MDSCs into tumors, thereby remodeling the immunosuppressive microenviron‑ ment (85).”
BackgroundInfluentialYi, C., Huang, S., Zhang, W., Guo, L., Xia, T., Huang, F., Yan, Y., Li, H., & Yu, B. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.107231 · Cited by 44
Tian, X.-Y., Xing, J.-W., Zheng, Q., & Gao, P. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.694443 · Cited by 45
“Bifidobacterium pseudolongum enhances antitumor immunity (Mager et al., 2020), exerts an anti-influenza effect (Zhang et al., 2020), enhances the efficacy of anti-CTLA4 treatment (Research, A.”
BackgroundInosine, gut microbiota, and cancer immunometabolism
Samami, E., Aleebrahim‐Dehkordi, E., Mohebalizadeh, M., Yaribash, S., Saghazadeh, A., & Rezaei, N. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00207.2022 · Cited by 45
Colorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
“Novel combinations, including the addition of radiotherapy, are anticipated to deliver promising results when expanding the use of ICI to a larger array of solid tumors; the results of these ongoing clinical trials are eagerly awaited.”
BackgroundInosine monophosphate and inosine differentially regulate endotoxemia and bacterial sepsis
Lovászi, M., Németh, Z. H., Gause, W. C., Beesley, J., Pacher, P., & Haskó, G. (2021) · The FASEB Journal · doi:10.1096/fj.202100862r · Cited by 41
Gut microbiota and its therapeutic implications in tumor microenvironment interactions
Feng, P., Xue, X., Bukhari, I., Qiu, C., Li, Y., Zheng, P., & Mi, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1287077 · Cited by 43
“Moreover, the status of B. pseudolongum has been reported to be associated with the response to ICB therapy, such as anti-CTLA-4 and anti-PD-L1, through its interaction with the adenosine A2A receptor on T cells (Mager and Burkhard, 2020).”
BackgroundSchubert, M., Rohrbach, R., Schmitt, M. W., & Stein‐Thoeringer, C. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670286 · Cited by 40
Gut Microbiome Signatures in the Progression of Hepatitis B Virus-Induced Liver Disease
Li, R., Yi, X., Yang, J., Zhu, Z., Wang, Y., Liu, X., Huang, X., Wan, Y., Fu, X., Shu, W., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.916061 · Cited by 53
Gut microbial metabolites in cancer therapy
Song, P., Peng, Z., & Guo, X. (2025) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.06.016 · Cited by 38
Plant-Based Diets and Cancer Risk: What is the Evidence?
DeClercq, V., Nearing, J. T., & Sweeney, E. (2022) · Current Nutrition Reports · doi:10.1007/s13668-022-00409-0 · Cited by 47
Wu, Z., Zhang, S., Li, L., Huang, Z., Huang, D., & Hu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.887383 · Cited by 44
“fragilis were associated with the response to CTLA-4 blockade (8), and Bifidobacterium was associated with the response to PD-L1 blockade (9, 10).”
BackgroundPushen capsule treatment promotes functional recovery after ischemic stroke
Zhang, Y., Shen, L., Xie, J., Li, L., Xi, W., Li, B., Bai, Y., Yao, H., Zhang, S., & Zhang, S. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154664 · Cited by 38
Jin, W., Jiang, L., Hu, S., & Zhu, A. (2024) · Aquaculture · doi:10.1016/j.aquaculture.2024.740581 · Cited by 38
Tumor Microenvironment in Melanoma—Characteristic and Clinical Implications
Sikorski, H., Zmijewski, M. A., & Piotrowska, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146778 · Cited by 38
“The association between enhanced efficacy of immunotherapies and the gut microbiota may also result from the stimulation of proinflammatory cytokine production and the secretion of tail length tape measure protein and inosine by bacteria, which augment T-cell responses [109,110].”
Microbiota-induced T cell plasticity enables immune-mediated tumour control
Najar, T. A., Hao, Y., Hao, Y., Romero‐Meza, G., Dolynuk, A., Almo, E., & Littman, D. R. (2026) · Nature · doi:10.1038/s41586-025-09913-z · Cited by 39
“Products of the microbiota, including metabolites 23–25 and innate receptor ligands 26 , may reprogramme myeloid cells 27 , lowering the activation threshold for antigen presentation and thereby facilitating priming and activation of tumour-reactive T cells.”
Computational methods and challenges in analyzing intratumoral microbiome data
Wang, Q., Liu, Z., Ma, A., Li, Z., Liu, B., & Ma, Q. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.01.011 · Cited by 37
“They exhibit broad effects on primary lymphoid organs [5,6], the TME [2,7,8], adaptive immune responses [9,10], and in fl ammatory responses in the intestines and other organs [11].”
BackgroundObata‐Ninomiya, K., Carrion, S. D. J., Hu, A. K., & Ziegler, S. F. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl6960 · Cited by 38
“It has been shown in other studies that antibody-mediated blockade of CTLA-4 and PD-1 effectively reduced the progression of AOM/DSS-induced CRC (62).”
ResultGut microbiota, an emergent target to shape the efficiency of cancer therapy
Kouidhi, S., Zidi, O., Belkhiria, Z., Raïs, H., Ayadi, A., Ayed, F. B., Mosbah, A., Cherif, A., & Gaaied, A. B. A. E. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00132 · Cited by 39
Zhang, H., Yang, L., Han, M., Han, Y., Jiang, Z., Zheng, Q., Dong, J., Wang, T., & Li, Z. (2024) · ACS Nano · doi:10.1021/acsnano.4c04553 · Cited by 39
Optimizing Cancer Treatment Through Gut Microbiome Modulation
Kim, K., Lee, M., Shin, Y., Lee, Y., & Kim, T. J. (2025) · Cancers · doi:10.3390/cancers17071252 · Cited by 40
“Inosine produced by B. pseudolongum enhances Th1 activation via the A2A receptor in murine CRC models, with its effect contingent on T cell costimulation, ultimately improving ICI efficacy [19].”
Lu, Y., Yuan, H., Liang, S., Li, D., Jiang, P., Wang, X., Zhang, K., & Liu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603658 · Cited by 45
Regulation of tissue-resident memory T cells by the Microbiota
Overacre-Delgoffe, A. E., & Hand, T. W. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00491-1 · Cited by 41
Vicentini, F., Szamosi, J. C., Rossi, L., Griffin, L., Nieves, K., Bihan, D. G., Lewis, I. A., Pittman, Q. J., Swain, M. G., Surette, M. G., et al. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.03.001 · Cited by 41
“Germ-free male C57Bl/6 mice (6 – 9 weeks of age) were provided by the University of Calgary International Microbiome Centre (Mager et al., 2020).”
MethodSelf-citationPatient-derived cancer models: Valuable platforms for anticancer drug testing
Genta, S., Coburn, B. A., Cescon, D. W., & Spreafico, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.976065 · Cited by 40
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
Pabst, L., Lopes, S., Bertrand, B., Creusot, Q., Kotovskaya, M., Pencreach, E., Beau‐Faller, M., & Mascaux, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087577 · Cited by 42
“Inosine seems to enhance the immune cells’ activation by adenosine A2 receptor, which promotes T1-cell differentiation in the population growth in the tumor microenvironment [132].”
BackgroundGuillot, N., Roméo, B., Manesh, S. S., Milano, G., Brest, P., Zitvogel, L., Hofman, P., & Mograbi, B. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.004 · Cited by 36
Diet-microbiome interactions in cancer
Abdeen, S. K., Mastandrea, I., Stinchcombe, N., Puschhof, J., & Elinav, E. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.013 · Cited by 36
Boesch, M., Horvath, L., Baty, F., Pircher, A., Wolf, D., Spahn, S., Straussman, R., Tilg, H., & Brutsche, M. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005401 · Cited by 38
The role of the symbiotic microecosystem in cancer: gut microbiota, metabolome, and host immunome
Xue, X., Li, R., Chen, Z., Li, G., Liu, B., Guo, S., Yue, Q., Yang, S., Xie, L., Zhang, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1235827 · Cited by 39
Resistance to immune checkpoint inhibitors in gastric cancer
Liu, K., Yuan, S., Wang, C., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1285343 · Cited by 38
Urolithin A Hijacks ERK1/2‐ULK1 Cascade to Improve CD8+ T Cell Fitness for Antitumor Immunity
Ma, S., Wu, Q., Wu, W., Tian, Y., Zhang, J., Chen, C., Sheng, X., Zhao, F., Ding, L., Wang, T., et al. (2024) · Advanced Science · doi:10.1002/advs.202310065 · Cited by 41
Maier, L., Stein‐Thoeringer, C. K., Ley, R. E., Brötz‐Oesterhelt, H., Link, H., Ziemert, N., Wagner, S., & Peschel, A. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(24)00049-1 · Cited by 40
Exploring the Role of the Gut Microbiota in Modulating Colorectal Cancer Immunity
Shakhpazyan, N. K., Михалева, Л. М., Bedzhanyan, A. L., Владиславовна, Г. З., Mikhalev, A. I., Midiber, K. Y., Pechnikova, V. V., & Biryukov, A. E. (2024) · Cells · doi:10.3390/cells13171437 · Cited by 37
“…[111] - Bifidobacterium pseudolongum [112] -Lactobacillales order [107] - Lactobacillus johnsonii [112] - Olsenella species [112] - Blautia genus [112] - Parabacteroides distasonis [106] - Alistipes genus [107] - Eubacterium rectale [118] - Roseburia spp. [118] -Methanobrevibacter [118] -…”
BackgroundInfluentialGut microbiota interact with breast cancer therapeutics to modulate efficacy
Arnone, A. A., Ansley, K. C., Heeke, A. L., Howard-McNatt, M. M., & Cook, K. L. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00185-0 · Cited by 44
“Intestinal B. pseudopodium modulated enhanced immunotherapy response through the production of the metabolite inosine (Mager et al, 2020).”
Targeted tumor therapy with L-cyst(e)ine-addicted bacteria-nanodrug biohybrids
Wang, Y., Chen, W., Han, Z., Zhang, S., Ji, P., Zhang, C., Liang, J., & Zhang, X. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.03.012 · Cited by 36
The Role of Gut Microbiota in Tumor Immunotherapy
Wu, M., Bai, J., Ma, C., Wei, J., & Du, X. (2021) · Journal of Immunology Research · doi:10.1155/2021/5061570 · Cited by 39
“Lactobacillus Johnsonii and Olsenella can significantly improve the efficacy of ICI in four cancer mouse models, which may be related to its metabolite, inosine [61].”
BackgroundPan, Y., Zhang, J., Xu, C., Liu, F., Cao, J., Chen, Y., Chen, W., & Luo, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643282 · Cited by 42
Gut microbiota therapy in gastrointestinal diseases
Ullah, H., Arbab, S., Chang, C., Bibi, S., Muhammad, N., Rehman, S. U., Suleman, S., Ullah, I., Hassan, I. U., Tian, Y., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1514636 · Cited by 41
“This highlights the critical role of microbiota-derived metabolites in immune regulation (Mager et al., 2020).”
Luo, Y., Chen, H., Huang, R., Wu, Q., Li, Y., & He, Y. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102049 · Cited by 37
Caffaratti, C., Plazy, C., Méry, G., Tidjani, A.-R., Fiorini, F., Thiroux, S., Toussaint, B., Hannani, D., & Gouëllec, A. L. (2021) · Metabolites · doi:10.3390/metabo11060406 · Cited by 40
Zhang, Y., Qin, S., Song, Y., Yuan, J., Hu, S., Chen, M., & Li, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857242 · Cited by 35
“Studies have shown that Lactobacillus johnsonii significantly enhanced efficacy of immune checkpoint inhibitors in four different mouse models of cancer (18).”
BackgroundZhao, H., Wang, D., Zhang, Z., Xian, J., & Bai, X. (2022) · Molecules · doi:10.3390/molecules27154799 · Cited by 38
“pseudolongum in intestine promoted the metabolism of the gut microbiota to produce inosine and increase the content of inosine in serum [72].”
BackgroundInfluentialReuniting philosophy and science to advance cancer research
Pradeu, T., Daignan‐Fornier, B., Ewald, A. J., Germain, P., Okasha, S., Plutynski, A., Benzekry, S., Bertolaso, M., Bissell, M. J., Brown, J. S., et al. (2023) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12971 · Cited by 44
“As far as the microbiome is concerned, in certain cancer types, microbes may transit from other body sites to reach tumours but can also exert immunological effects from afar (Mager et al., 2020; Lam et al., 2021).”
BackgroundXie, N., Wang, Z., Shu, Q., Liang, X., Wang, J., Wu, K., Nie, Y., Shi, Y., Fan, D., fan, D., et al. (2023) · Nutrients · doi:10.3390/nu15132937 · Cited by 40
“In mouse models, Bifidobacterium pseudolongum was found to enhance immune checkpoint inhibitor efficacy by producing inosine to promote Th1 transcriptional differentiation [12].”
BackgroundFrom nature to clinic: Quercetin’s role in breast cancer immunomodulation
Fang, L., Gao, D., Wang, T., Zhao, H., Zhang, Y., & Wang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1483459 · Cited by 36
Current status and future perspective of immune checkpoint inhibitors in colorectal cancer
Zhou, C., Cheng, X., & Tu, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.023 · Cited by 37
Microbiome influencers of checkpoint blockade–associated toxicity
Wang, Y., Jenq, R. R., Wargo, J. A., & Watowich, S. S. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220948 · Cited by 37
“These studies found improved activation of antigen-presenting dendritic cells (DCs) and enhanced tumor infiltration of CD4+ and CD8+ T cells in the context of favorable taxa or microbiomes (Mager et al., 2020; Matson et al., 2018; Routy et al., 2018b; Sivan et al., 2015; Tanoue et al., 2019) or, conversely, reduced pr…”
BackgroundInfluentialSepich‐Poore, G. D., Guccione, C., Laplane, L., Pradeu, T., Curtius, K., & Knight, R. (2022) · BioEssays · doi:10.1002/bies.202100252 · Cited by 33
Zhuang, Y.-P., Zhou, H., Chen, H., Zheng, M.-Y., Liang, Y., Gu, Y.-T., Li, W., Qiu, W., & Zhou, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115040 · Cited by 37
Microbiota as the unifying factor behind the hallmarks of cancer
Benešová, I., Křížová, Ľ., & Kverka, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05244-6 · Cited by 35
“Cyclophosphamide, for example, enables translocation of selected G + bacteria to lymph nodes by disrupting the integrity of the intestinal epithelium, thereby inducing IFN-γ + IL-17 + Th cells that can slow down tumor growth (Viaud et al. 2013).”
BackgroundInfluentialNeuroactive metabolites modulated by the gut microbiota in honey bees
Cabirol, A., Moriano‐Gutierrez, S., & Engel, P. (2023) · Molecular Microbiology · doi:10.1111/mmi.15167 · Cited by 39
“Adenosine and other nucleosides can be produced by gut bacteria from the breakdown of available nucleotides, in particular, members of Bifidobacterium and Lactobacillus have been described as adenosine producers (Li et al., 2023; Mager et al., 2020).”
Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response
Trepka, K. R., Olson, C. A., Upadhyay, V., Zhang, C., & Turnbaugh, P. J. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022724-100847 · Cited by 36
“Bifidobacterium pseudolongum promotes an α -CTLA4 immunotherapy response in GF mice implanted with MC38 colon cancer cells (77).”
InfluentialZhang, S., Wang, X., Cai, Q.-Q., Chen, C., Zhang, Z.-Y., Xu, Y., Yang, M., Jia, Q.-A., Wang, Y., & Wang, Z.-M. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01137-1 · Cited by 37
“However, notable individual variations manifest in patients’ responses to these treatments, with differences in gut microbiota considered a potential key factor in this variability 7,10 .”
Liao, K., Wen, J., Liu, Z., Zhang, B., Zhang, X., Fu, Y., Zhang, W., Hu, H., Ai, K., Zhu, W., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102820 · Cited by 40
Luo, B., Zhang, Y., Zhang, C., Liu, X., & Shi, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.001 · Cited by 34
Queen, J., Shaikh, F. Y., & Sears, C. L. (2023) · Nature Cancer · doi:10.1038/s43018-023-00602-2 · Cited by 36
Wang, Q., Shen, X., Chen, G., & Du, J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34464 · Cited by 38
“For example, Bifidobacterium pseudolongum, an important commensal bacterium, promoted the activation of T helper 1 cells, significantly increasing the sensitivity of murine CRC models to ICI treatment.(96) In addition, Bacteroides_sp.”
BackgroundEmerging roles of the gut microbiota in cancer immunotherapy
Shi, Z., Li, H., Song, W., Zhou, Z., Li, Z., & Zhang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139821 · Cited by 34
“epithelial tumors, which was dependent on T cell expression of the adenosine A2A receptor to promote Th1 cell activation (65).”
BackgroundRaman, M., Vishnubhotla, R. V., Ramay, H. R., Gonçalves, M. C. B., Shin, A., Pawale, D., Subramaniam, B., & Sadhasivam, S. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-03935-8 · Cited by 36
“Metabolomics Metabolomics were performed as described previously [35, 36].”
MethodSelf-citationGut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors
Wang, J., Zhu, N., Su, L., & Yang, R. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216582 · Cited by 37
Adenosine in Intestinal Epithelial Barrier Function
Stepanova, M., & Aherne, C. M. (2024) · Cells · doi:10.3390/cells13050381 · Cited by 35
“In Bifidobacterium pseudo-longum –monocolonized mice, the production of inosine appears to exist in a gradient, with high levels in the duodenum, followed by a gradual decrease along the jejunum and cae-cum [126].”
BackgroundBacterial microcompartments and energy metabolism drive gut colonization by Bilophila wadsworthia
Sayavedra, L., Yasir, M., Goldson, A. J., Brion, A., Gall, G. L., Moreno‐Gonzalez, M., Altera, A., Paxhia, M. D., Warren, M. J., Savva, G. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60180-y · Cited by 38
“However, since inosine can also be synthesised by some human microbiome members, including B. longum 44 , the reduced abundance of inosine in the SIHUMI+Bw group might also result from shifts in the abundance and gene expression of the SIHUMI consortia due to the presence of B. wadsworthia .”
Translating Microbiome Research From and To the Clinic
Zhang, Z. J., Lehmann, C. J., Cole, C. G., & Pamer, E. G. (2022) · Annual Review of Microbiology · doi:10.1146/annurev-micro-041020-022206 · Cited by 33
Influence of Microbiota on Tumor Immunotherapy
Yu, X., Li, W., Li, Z., Wu, Q., & Sun, S. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91771 · Cited by 37
“Moreover, the disruption of the intestinal barrier function by anti-CTLA4 treatment was found to be vital for the systemic translocation of adenosine derived from Bifidobacterium , consequently promoting Th1 activation and anti-tumor immunity via T cell-specific A2AR signaling [212].”
BackgroundYu, H., Lin, G., Jiang, J., Yao, J., Pan, Z., Xie, H., Bo, Z., He, Q., Yang, J.-H., Chen, Z., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2410474 · Cited by 35
Zhang, C., Wang, Y., Cheng, L., Cao, X., & Liu, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1557959 · Cited by 42
Zhang, M., Wei, Z., Wei, B., Lai, C., Zong, G., Tao, E., Fan, M., Pan, Y., Zhou, B., Shen, L., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.04.022 · Cited by 35
HLA-A29 and Birdshot Uveitis: Further Down the Rabbit Hole
Kuiper, J. J. W., & Venema, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.599558 · Cited by 32
“For example, CD8+ T cells are primed by microbial derived metabolites and MHC-I presented microbial derived peptides to cross-react with cancer antigens as a means to facilitate anti-tumor immunity (117, 118).”
BackgroundKlassen, L., Xing, X., Tingley, J. P., Low, K. E., King, M. L., Reintjes, G., & Abbott, D. W. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.632684 · Cited by 34
“, 2018), including improving responsiveness to chemotherapy (Mager et al., 2020).”
BackgroundWan, L., Wu, C., Wu, Q. J., Luo, S., Liu, J., & Xie, X. (2022) · Cancer Medicine · doi:10.1002/cam4.4994 · Cited by 33
Exploration of the link between gut microbiota and purinergic signalling
Li, M., Liu, B., Li, R., Yang, P. C., Leng, P., & Huang, Y. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09891-1 · Cited by 34
“Abbreviations ATP: Adenosine 5′-triphosphate; eATP: Extracellular Adenosine triphosphate; GTP: 5′-Triphosphate; NAD: Nicotinamide adenine dinucleotide; IMP: Inosine monophosphate; XMP: Xanthosine monophosphate; GMP: Guanosine monophosphate; HPRT: Hypoxanthine–guanine phosphoribosyltransferase; APRT: Adenine phosphorib…”
BackgroundInfluentialThe role of the sex hormone-gut microbiome axis in tumor immunotherapy
Wang, L., Tang, L., Zhai, D., Song, M., Li, W., Xu, S., Jiang, S., Meng, H., Liang, J., Wang, Y., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185035 · Cited by 34
Exploring the Involvement of Gut Microbiota in Cancer Therapy-Induced Cardiotoxicity
Kunika, Frey, N., & Rangrez, A. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087261 · Cited by 34
“pseudolongum produces the metabolite inosine, which, by acting on the adenosine A2A receptor on T cells, significantly promotes Th1 cell differentiation in the presence of exogenous IFN-γ and improves the therapeutic response to immune checkpoint inhibitor (ICI) therapy, including anti-CTLA-4 and anti-PD-L1 [56].”
BackgroundMetabolomics strategy for diagnosing urinary tract infections
Chan, C. C. Y., Gregson, D. B., Wildman, S. D., Bihan, D. G., Groves, R. A., Aburashed, R., Rydzak, T., Pittman, K., Bavel, N. V., & Lewis, I. A. (2025) · Nature Communications · doi:10.1038/s41467-025-57765-y · Cited by 32
Self-citationTumor-resident microbes: the new kids on the microenvironment block
Li, L., Chandra, V., & McAllister, F. (2024) · Trends in Cancer · doi:10.1016/j.trecan.2023.12.002 · Cited by 30
“In addition, intratumoral Bifidobacterium pseudolongum-derived inosine induces T cell activation and enhances the CRC response to immunotherapy because inosine signaling in T cells via the adenosine 2A receptor drives activation of type 1 T helper (Th1) cells and antitumor immunity [53].”
BackgroundMicrobiota-targeted therapies in inflammation resolution
Strati, F., Lattanzi, G., Amoroso, C., & Facciotti, F. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101599 · Cited by 33
Gut–lung axis: role of the gut microbiota in non-small cell lung cancer immunotherapy
Zhang, H., & Xu, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1257515 · Cited by 33
The role of microbiomes in gastrointestinal cancers: new insights
Yarahmadi, A., & Afkhami, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1344328 · Cited by 30
“Contrarily, much research has also surfaced, demonstrating that gut commensal bacteria can enhance ICB treatment by activating antitumor T cells (105 – 107).”
BackgroundAbdi, A., Oroojzadeh, P., Valivand, N., Sambrani, R., & Lotfi, H. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149632 · Cited by 37
Zhang, H., Wang, J., Shen, J., Chen, S., Yuan, H., Zhang, X., Liu, X., Yu, Y., Li, X., Gao, Z., et al. (2024) · iMeta · doi:10.1002/imt2.220 · Cited by 37
“While previous studies have reported that bacteria such as Bifidobacter-ium pseudolongum [35], in addition to B. infantis can produce inosine to potentially enhance the antitumor effect of immune checkpoint blockade, further investigation is required to determine if B. infantis alone or in…”
Result
Metadata
- Authors
- Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., Lewis, I. A., Geuking, M. B., & McCoy, K. D.
- Affiliations
- University of Calgary (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Mager, Lukas F.
- McCoy, Kathy D.
- ORCID
- Venue
- Science
- Published
- 2020-09-18
- Volume
- 369
- Issue
- 6510
- Pages
- 1481-1489
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3049052172
- Semantic Scholar
- 041ece73120d89c36e2870fa3f1b95b4ebdafab2
- Cited by
- 1,407
- References
- 65
- Citations by year
- 2026: 240 · 2025: 280 · 2024: 260 · 2023: 247 · 2022: 220 · 2021: 134 · 2020: 25
- FWCI
- 56.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (PJT-165930, PJT-156073)
- Natural Sciences and Engineering Research Council of Canada
- Swiss National Science Foundation
- Alberta Innovates
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- inosine, gut microbiota, immune checkpoint inhibitors, cancer immunotherapy, antitumor immunity, microbial metabolites, T cell activation, colorectal cancer, bladder cancer, melanoma, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Lactobacillus johnsonii, Animals, Antibodies, Bifidobacterium, Urinary Bladder Neoplasms, Female, Immunotherapy, Inosine, Intestinal Neoplasms, Male, Melanoma, Mice, Inbred C57BL, Neoplasms, Experimental, Skin Neoplasms, T-Lymphocytes, Receptor, Adenosine A2A, Mice, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.